HDL therapies — past, present and future
Journal Title: Journal of Medicines Development Sciences - Year 2015, Vol 1, Issue 2
Abstract
For a number of years, high-density lipoprotein (HDL) has been recognized to have an athero-protective role by promoting reverse lipid transport, a process facilitating the cholesterol efflux from atherosclerotic plaques in the artery wall and its elimination by the liver via biliary excretion. On the contrary, low-density lipoprotein (LDL) particles carry cholesterol to the organs and tissues where it can be used to produce hormones or maintain cell metabolism. When an imbalance develops, as a result of either an excess level of cholesterol associated with LDL (LDL-C) or a less effective cholesterol elimination by HDL (HDL-C), this causes an excess of cholesterol to be transported to the tissues and promotes the deposition of cholesterol. This often occurs in the artery walls, particularly in the coronary arteries. There is no approved medical treatment for directly suppressing or treating the atherosclerotic plaque once it is formed. Epidemiological studies have shown that the risk of developing cardio-vascular disease (CVD) is higher in patients with low levels of HDL-C regardless of LDL-C levels, even in patients optimally treated with LDL-C-lowering therapies. These data highlight that low HDL-C and low HDL particle number is an important target of therapies aiming to reduce the residual risk of CVD.
Authors and Affiliations
Ronald Barbaras
Keywords
Related Articles
- EP ID EP679248
- DOI -
- Views 204
- Downloads 0
Brazil is gaining its momentum in pharmaceutical development
Brazil is one of the world’s largest economies and pharmaceutical markets, having the Brazilian government as an important purchaser. There are strong local companies that have grown sustainably after the introduction of...
TransCelerate: a global collaboration across biopharmaceutical R&D to accelerate and simplify new medicines development
As the economic pressures increase on healthcare systems around the world due to aging populations, chronic diseases, expanding patient populations in emerging markets and advances in medical technology, it is crucial th...
EUPATI: Collaboration between patients, academia and industry to champion the informed patient in the research and development of medicines
The value of collaborations and partnerships between different stakeholders to achieve optimum outcomes in the medicines research and development process is being recognised. Historically, there has been a lack of collab...
The Faculty of Pharmaceutical Medicine – Foundation, function and future
The Faculty of Pharmaceutical Medicine was established in the United Kingdom (UK) in 1989 to develop and maintain competence, ethics and the highest professional standards of practice in the discipline. This article char...
Determination of Genistin Content in Flemingia philippinensis Merr. et Rolfe by High Performance Liquid Chromatography (HPLC)
To set up the HPLC method in determination of the genistin content in Flemingia philippinensis Merr. et Rolfe. Method: Extract and filter the crushed Flemingia philippinensis Merr. et Rolfe that has been soaked in methan...